News | November 01, 2022
Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Revenue from operations up 26% to Rs. 768 crores
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
Subscribe To Our Newsletter & Stay Updated
